drugset / Trial / NCT01681576

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

NCT01681576

Phase 2 Completed 72 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blind

Summary

This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.

Timeline

Start
2012-08
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 400 mg Oral
Subject Valsartan Small molecule 320 mg Oral

Indications